Page 1 | Search Results | Blood Advances | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

Kathelijn Fischer, Gili Kenet, Karin Kurnik, Manuel Carcao, Johannes Oldenburg, Torben Stamm-Mikkelsen, Ana Rosa Cid Haro, Minna Koskenvuo, Jan Blatny, Christoph Königs

Blood Adv (2024) 8 (2): 369–377.

https://doi.org/10.1182/bloodadvances.2023011442

Published: 2024

Includes: Supplemental data

Journal Articles

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Amy D. Shapiro, Roshni Kulkarni, Margaret V. Ragni, Hervé Chambost, Johnny Mahlangu, Johannes Oldenburg, Beatrice Nolan, Margareth C. Ozelo, Meredith C. Foster, Annemieke Willemze, Christopher Barnowski, Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, K. John Pasi

Blood Adv (2023) 7 (13): 3049–3057.

https://doi.org/10.1182/bloodadvances.2022009230

Published: 2023

Includes: Supplemental data

Journal Articles

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz-Priel, Guy Young, Víctor Jiménez-Yuste

Blood Adv (2022) 6 (24): 6140–6150.

https://doi.org/10.1182/bloodadvances.2022007458

Published: 2022

Includes: Supplemental data

Journal Articles

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić-Šalek, Johannes Oldenburg, Pratima Chowdary

Blood Adv (2022) 6 (11): 3422–3432.

https://doi.org/10.1182/bloodadvances.2021006403

Published: 2022

Includes: Supplemental data

Journal Articles

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

Hamideh Yadegari, Muhammad Ahmer Jamil, Jens Müller, Natascha Marquardt, Orla Rawley, Ulrich Budde, Osman El-Maarri, David Lillicrap, Johannes Oldenburg

Blood Adv (2022) 6 (3): 1038–1053.

https://doi.org/10.1182/bloodadvances.2021005895

Published: 2022

Includes: Multimedia, Supplemental data

Journal Articles

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

Katrin J. Czogalla, Kerstin Liphardt, Klara Höning, Veit Hornung, Arijit Biswas, Matthias Watzka, Johannes Oldenburg

Blood Adv (2018) 2 (6): 691–702.

https://doi.org/10.1182/bloodadvances.2017006775

Published: 2018

Includes: Supplemental data

NARROW

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

Email alerts

ASH Publications

American Society of Hematology

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only